Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel

被引:66
作者
Cheng, L
Zhu, H
Wang, A
Ren, F
Chen, J
Glasier, A
机构
[1] Univ Edinburgh, Ctr Reprod Biol, Dept Obstet & Gynaecol, Edinburgh EH3 9ET, Midlothian, Scotland
[2] Int Peace Matern & Child Hlth Hosp, Shanghai Inst Family Planning Tech Instruct, Shanghai, Peoples R China
[3] Jiaxing Reprod Hlth Care Ctr, Shanghai, Peoples R China
关键词
bleeding; contraception; implants; mifepristone; progestin-only;
D O I
10.1093/humrep/15.9.1969
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
It has been suggested that the administration of an antiprogesterone might improve bleeding patterns in women with irregular bleeding while using low-dose progestin-only contraception. We report the findings of a double-blind, randomized, placebo-controlled trial of mifepristone 50 mg taken once every 4 weeks in 100 Chinese women (50 subjects and 50 controls) complaining of frequent and irregular bleeding while using a levonorgestrel-releasing subdermal contraceptive implant. In all women, regardless of treatment, the frequency of bleeding decreased significantly over 360 days of observation. Women recorded significantly shorter episodes of bleeding (P < 0.0002) during mifepristone treatment than during the 90 days before treatment started. In contrast, the duration of bleeding episodes fell more gradually in placebo-treated controls. Women using mifepristone were more likely to find treatment acceptable than women receiving a placebo tablet (P < 0.01), Despite concern that anti-progestogenic effects may jeopardize contraception, there were no pregnancies. This approach may offer a useful strategy to improve continuation rates by alleviating unwanted side-effects until bleeding patterns improve spontaneously with time.
引用
收藏
页码:1969 / 1972
页数:4
相关论文
共 13 条
[1]   TREATMENT WITH NORPLANT SUBDERMAL IMPLANTS INHIBITS SPERM PENETRATION THROUGH CERVICAL-MUCUS INVITRO [J].
CROXATTO, HB ;
DIAZ, S ;
SALVATIERRA, AM ;
MORALES, P ;
EBENSPERGER, C ;
BRANDEIS, A .
CONTRACEPTION, 1987, 36 (02) :193-201
[2]  
DIAZ S, 1990, CONTRACEPTION, V42, P97
[3]  
Edwards RG, 1996, HUM REPROD, V11, P1
[4]  
FANG KJ, 1998, CHINESE J FAM PLAN, V33, P11
[6]   Norplant® consensus statement and background review [J].
Fraser, IS ;
Tiitinen, A ;
Affandi, B ;
Brache, V ;
Croxatto, HB ;
Diaz, S ;
Ginsburg, J ;
Gu, SJ ;
Holma, P ;
Johansson, E ;
Meirik, O ;
Mishell, DR ;
Nash, HA ;
von Schoultz, B ;
Sivin, I .
CONTRACEPTION, 1998, 57 (01) :1-9
[7]  
FRASER LS, 1997, HUM REPROD, V11, P165
[8]   Changes in vascular basement membrane in the endometrium of Norplant users [J].
Hickey, M ;
Simbar, M ;
Markham, R ;
Young, L ;
Manconi, F ;
Russell, P ;
Fraser, IS .
HUMAN REPRODUCTION, 1999, 14 (03) :716-721
[9]   A longitudinal study of changes in endometrial microvascular density in Norplant® implant users [J].
Hickey, M ;
Simbar, M ;
Young, L ;
Markham, R ;
Russell, P ;
Fraser, IS .
CONTRACEPTION, 1999, 59 (02) :123-129
[10]  
SHOUPE D, 1991, FERTIL STERIL, V55, P766